Recent reports suggest that cancer control may worsen if erythropoietin is administered. We investigated whether erythropoietin receptor expression on cancer cells may correlate with this unexpected finding.
INTRODUCTION
Anemia has been consistently associated with poor outcome of cancer patients. 1 Because of its potential to correct anemia and associated symptoms erythropoietin has been increasingly prescribed to these patients. However, two large multicenter trials recently reported decreased survival and disease control following erythropoietin treatment in patients with cancer of the breast 2 and of the head and neck. Methodological issues may have played a role, but a "protective effect" of erythropoietin on cancer cells has also been discussed. In a subset of 154 patients from one clinical center of the head and neck trial, 3 we explored whether the adverse effect of epoetin beta was restricted to patients with erythropoietin receptor (EpoR) expression on cancer.
PATIENTS AND METHODS

Patients
Head and neck cancer patients enrolled in a previously reported clinical trial 3 treated at the Department of Radiooncology at the University Clinic, Freiburg, Germany, were included in this study. The trial was approved by the local ethics committee and performed in accordance with the revised Declaration of Helsinki and good clinical practice guidelines.
Patient selection criteria, treatment parameters, follow-up schedule, and evaluation methods are described in detail in a former publication.
3 Details of this subpopulation are specified elsewhere. 4 Briefly, the study was double-blind, randomized and placebo-controlled. Main inclusion criteria were a decreased blood hemoglobin concentration at random assignment (Ͻ 13 g/dL in men; Ͻ 12 g/dL in women), T3 or T4 tumors or nodal involvement, and definitive radiation therapy alone or postoperative radiotherapy. For the purpose of random assignment, patients were stratified according to resection status: stratum 1, postoperative radiation following complete (R0) resection; stratum 2, postoperative radiation of incompletely resected (R1 or R2) disease; and stratum 3, primary definitive radiotherapy. We administered 60 Gy following complete resection (R0), 64 Gy (allowable range for both, 56 to 64 Gy) to R1-resected tumors and 70 Gy (allowable range, 66 to 74 Gy) to macroscopically incompletely (R2) resected disease or for definitive treatment, respectively. Epoetin beta (300 U/kg) or placebo was administered three times per week and started 10 to 14 days before radiotherapy. Drug was continued throughout the radiotherapy course. Additionally, 200 mg iron (III) saccharate (Ferrum Hausmann, Vifor, St Gallen, Switzerland) was applied intravenously once weekly if the transferrin saturation was lower than 25%. Treatment was discontinued when target hemoglobin levels (Ն 14 g/dL in women; Ն 15 g/dL in men) were achieved or when the hemoglobin increased more than 2 g/dL within 1 week; it was resumed if the blood hemoglobin level fell below target level. Patients were seen for follow-up at 3-month intervals to assess locoregional cancer control and survival under blinded conditions. Complete follow-up data are available through March 2004.
Immunohistochemistry
Formalin-fixed paraffin-embedded tissue sections obtained before treatment were assayed for EpoR expression retrospectively. Histopathologic diagnosis of squamous cell carcinoma of the samples was confirmed before immunohistochemical processing. We used the DAKO (Carpinteria, CA) Autostainer with ChemMate Detection Kit DAKO 5005 for immunohistochemistry. Following deparaffinization with xylol, alcohol, and rehydration, slides were reacted for 30 minutes with target retrieval solution (DAKO S1699; pH 6). Endogenous biotin was blocked using the DAKO biotin blocking system. Slides were then incubated for 30 minutes with a polyclonal rabbitantihuman EpoR antibody (1:200 dilution; C-20; Santa Cruz Biotechnologies, Santa Cruz, CA). Thereafter, biotinylated goat antirabbit immunoglobulin was applied for 15 minutes, followed by alkaline phosphatase/streptavidin for another 15 minutes. Slides were developed with alkaline phosphatase/fast red and counterstained with hemalaun for 6 minutes. We used fetal kidney sections for positive control and omitted the primary antibody for negative controls, respectively. Additionally, staining of endothelial or basal cells of the mucous membranes in individual sections was used as internal control.
Two independent reviewers unaware of all clinical data performed tissue processing and scoring of the slides. Differences between the two investigators were resolved by consensus. Applying a four-grade scale we evaluated semiquantitatively the expression intensity and proportion of positive-staining cells on the entire tissue section. Cytoplasmatic or membrane staining was considered positive. Missing staining of cancer cell was considered as score 0. Score 1 showed barely, score 2, moderate, and score 3, strong cellular staining. Any positive reaction required at least 10% of cancer cells to stain.
For further analyses scores 0 and 1 were regarded as negative and scores 2 and 3 as positive (Fig 1) .
Statistical Methods
Locoregional progression-free survival was analyzed as primary end point. Progression was assumed if the tumor recurred or if its size increased by more than 25%. Standard censored failure time data techniques were used.
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Kaplan-Meier curves 6 were calculated with event times being the time until locoregional progression or death, whichever occurred first. Subjects who neither died nor had progressing cancer within the irradiated volume were censored at time of their last follow-up. Comparisons between survival curves for epoetin beta treatment versus placebo were based on the stratified log-rank test with stratification for resection status. Additional stratification for American Joint Committee on Cancer stage (not shown here) produced similar results. Comparisons were done separately for patients, with cancer staining positive for EpoR and for patients whose cancers did not.
Relative risks were calculated using the Cox proportional hazards regression model. 7 Treatment was entered as a binary variable (1 for epoetin beta and 0 for placebo). A simple model including only treatment arm and stratified by resection status provided adjusted relative risks that correspond to the KaplanMeier analyses. This was done separately for receptor-positive and -negative patients. A model that included all patients in a single analysis evaluated treatment arm and receptor status together while including resection status as a three-level variable. A model with interaction term between receptor status and treatment arm allowed different treatment relative risks for receptorpositive versus -negative patients. Its log partial likelihood was compared with that of a model without interaction in order to test whether the treatment relative risks differed significantly with receptor status. The log partial likelihood ratio test was used.
RESULTS
Between March 1997 and April 2001 we randomly assigned 157 patients. Tissuesampleswereavailablefor154patients.Samplesstainedpositivefor erythropoietin receptors in 104 patients and negative in 50 patients. Table 1 presents characteristics of patients by treatment assignment within the two groups of patients-receptor positive and receptor negative. For the most part, characteristics of patients assigned to treatment with epoetin beta were similar to those assigned placebo. There was some imbalance in regards to resection stratum. For receptor-positive patients, there were more high-risk patients (radiation treatment without surgery) on the epoetin beta arm, while for receptor negative patients, more high-risk patients were on the placebo arm. However, since our analysis stratified on resection status, this did not confound our results. Consistent with the analysis of the entire trial, in the subset of patients enrolled from our center, treatment with epoetin beta was associated with decreased locoregional progression-free survival (adjusted relative risk, 1.58; P ϭ .02). Figure 2 shows this effect for patients with receptor positive and negative cancer. The negative impact of epoetin beta appears to be restricted to patients whose cancers expressed EpoR. The resection status adjusted relative risks for locoregional failure or death were 2.07 (P Ͻ .01) for receptor positive patients and 0.94 (P ϭ .86) for receptor negative patients (treatment group v placebo). Note that any imbalances between treatment and placebo in resection status do not contribute to these relative risks as they have been adjusted for through stratification. Table 2 presents the results of a Cox regression analysis that includes all patients and models the effects of resection status and receptor status as constants over time. Resection status is clearly associated with locoregional progression-free survival. The analysis confirms that after adjustment for the resection status, epoetin beta treatment is associated with increased risk of loco-regional progression or death for patients with receptor-positive cancers (relative risk, 1.4/0.7 ϭ 2.0; P ϭ .003) but not in those with receptor-negative cancers (relative risk, 0.98; P ϭ .95). These relative risks are almost statistically significant (P ϭ .08) based on the Cox partial likelihood ratio test.
DISCUSSION
Recently, a negative impact of erythropoietin on cancer control and survival was reported from two large multicenter trials.
2,3 These observations have been questioned and concerns were raised about methodologic problems that may have contributed to the findings, but little attention has been given to possible biologic explanations.
Cancer cells are known to express EpoR, 8-12 the expression of which seem to correlate to cellular dedifferentiation. 8 Furthermore, erythropoietin may bind to EpoR in these cells and activate STAT5 and NF-B signal transduction pathways, [13] [14] [15] [16] as in normal nonhematopoetic tissues. 17, 18 Ultimately increased cancer cell proliferation, 13, 19, 20 migration 21 and clonogenicity 22 will evolve. Comparably, our clinical data suggest that particular cellular features may underly the unexpected findings of the head and neck cancer trial since we found that the negative impact of epoetin beta was restricted to patients with cancer staining positive for EpoR.
It is of note that patients treated with placebo experienced different outcome depending on whether their cancer cells expressed EpoR or not. However, this was not statistically significant (P ϭ .17) and may indicate possible effects of endogenous erythropoietin levels that show substantial variations.
10 Further, though the small sample size may limit our conclusions, essential methodological pitfalls do not confound our observations: Clinical baseline characteristics were reasonably balanced, immunohistochemical processing was verified by adequate controls and the evaluation was unbiased because two independent researchers, blinded for all clinical parameters, scored the sections. It should be mentioned that, although we applied a simplified scoring system, our results could be confirmed when applying published scoring protocols 23 (data not shown). The specificity of the antibody used in this study was recently questioned. 24 In ours and other 9, 11, 12, 25, 26 studies, it reliably detects cells known to express erythropoietin receptors in paraffin embedded tissue sections and Western blots identified the appropriate protein. 8 Aside, however, from potential doubts on the molecular specificity of this antibody a correlation of immunohistochemical findings to clinical outcome suggests that biologic phenomena may explain the recently reported "negative erythropoietin trials."
We conclude that EpoR is variably expressed on head and neck cancer cells and is associated with a detrimental effect of epoetin beta administration. A possible mechanism is that stimulation with recombinant erythropoietin protects residual tumor from radiation treatment. It might reassure that epoetin beta did not affect the clinical course of patients with EpoR-negative cancer. Further research should confirm our findings and elucidate the underlying mechanisms.
All researchers contributed to design and implementation of the study and to data collection. D. Mattern and C. Bézay performed histopathological analyses. M. Pepe analyzed the data and M. Henke drafted the report. All researchers took part in the critical revision of the manuscript and approved its final version. 
EpoR (erythropoietin receptor):
A receptor found on the surface of erythroid progenitor cells in the bone marrow that when bound with erythropoietin, stimulates erythroid progenitor cells to transform into erythrocytes.
Immunohistochemistry:
The application of antigenantibody interactions to histochemical techniques. Typically, a tissue section is mounted on a slide and is incubated with antibodies (polyclonal or monoclonal) specific to the antigen (primary reaction). The antigen-antibody signal is then amplified using a second antibody conjugated to a complex of peroxidase-antiperoxidase (PAP), avidin-biotin-peroxidase (ABC) or avidin-biotin alkaline phosphatase. In the presence of substrate and chromogen, the enzyme forms a colored deposit at the sites of antibody-antigen binding. Immunofluorescence is an alternate approach to visualize antigens. In this technique, the primary antigen-antibody signal is amplified using a second antibody conjugated to a fluorochrome. On UV light absorption, the fluorochrome emits its own light at a longer wavelength (fluorescence), thus allowing localization of antibody-antigen complexes.
Locoregional progression-free survival: The Table 1 , under EpoR-Postive/Epotein Beta, the range for age was given as "43-115," whereas it should have been "43-76." Also, the quartiles for age were given as "57, 67, 74," whereas they should have read "55, 60, 65." 
